Cadrenal Therapeutics (CVKD) Stock Forecast, Price Target & Predictions
CVKD Stock Forecast
Cadrenal Therapeutics stock forecast is as follows: an average price target of $32.00 (represents a 120.84% upside from CVKD’s last price of $14.49) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CVKD Price Target
The average price target for Cadrenal Therapeutics (CVKD) is $32.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $32.00. This represents a potential 120.84% upside from CVKD's last price of $14.49.
CVKD Analyst Ratings
According to 1 Wall Street analysts, Cadrenal Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CVKD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cadrenal Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | Joseph Pantginis | H.C. Wainwright | $32.00 | $14.93 | 114.33% | 120.84% |
The latest Cadrenal Therapeutics stock forecast, released on Nov 11, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $32.00, which represents a 114.33% increase from the stock price at the time of the forecast ($14.93), and a 120.84% increase from CVKD last price ($14.49).
Cadrenal Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $32.00 | $32.00 |
| Last Closing Price | $14.49 | $14.49 | $14.49 |
| Upside/Downside | -100.00% | 120.84% | 120.84% |
In the current month, the average price target of Cadrenal Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cadrenal Therapeutics's last price of $14.49. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Cadrenal Therapeutics's last stock rating was published by H.C. Wainwright on Nov 11, 2024. The company gave CVKD a "Buy" rating, the same as its previous rate.
Cadrenal Therapeutics Financial Forecast
Cadrenal Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Cadrenal Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CVKD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Cadrenal Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict CVKD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cadrenal Therapeutics's previous annual EBITDA (undefined) of $NaN.
Cadrenal Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-1.57M | $-1.53M | $-1.39M | $-2.37M | $-2.23M | $-2.13M | $-1.36M |
| High Forecast | $-1.57M | $-1.53M | $-1.39M | $-2.37M | $-1.84M | $-2.13M | $-1.36M |
| Low Forecast | $-1.57M | $-1.53M | $-1.39M | $-2.37M | $-2.65M | $-2.13M | $-1.36M |
| Surprise % | - | - | - | - | - | - | - |
Cadrenal Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CVKD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Cadrenal Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Cadrenal Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CVKD last annual SG&A of $NaN (undefined).
Cadrenal Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-1.42 | $-1.39 | $-1.26 | $-2.15 | $-2.02 | $-1.93 | $-1.27 |
| High Forecast | $-1.42 | $-1.39 | $-1.26 | $-2.15 | $-1.67 | $-1.93 | $-1.27 |
| Low Forecast | $-1.42 | $-1.39 | $-1.26 | $-2.15 | $-2.40 | $-1.93 | $-1.27 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Cadrenal Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CVKD previous annual EPS of $NaN (undefined).
Cadrenal Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| GPCR | Structure Therapeutics | $31.48 | $99.00 | 214.49% | Buy |
| CVKD | Cadrenal Therapeutics | $11.45 | $32.00 | 179.48% | Buy |
| FHTX | Foghorn Therapeutics | $5.51 | $14.00 | 154.08% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| IKT | Inhibikase Therapeutics | $3.97 | $6.50 | 63.73% | Buy |
| SABS | SAB Biotherapeutics | $4.03 | $5.67 | 40.69% | Buy |
| CNTA | Centessa Pharmaceuticals | $17.60 | $23.25 | 32.10% | Buy |
| MNPR | Monopar Therapeutics | $30.68 | $29.50 | -3.85% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |
| XCUR | Exicure | $18.53 | $12.00 | -35.24% |